Screening Multitarget Anticancer Compounds from Salicylic Acid Derivatives: (Without and with Amino Acid Linkage) by In Silico Docking

Abstract:

This research aims to design anticancer molecules using the hybridization concept based on molecular derivatives of salicylic acid. The investigation explores structures with and without linked amino acid alanine through an in-silico docking approach. The research conducts screenings of the designed salicylic acid derivative molecules against receptors, including MMP9, MMP2, CDK2, P53, BAK EGFR, and ADP Ribose Polymerase. The most promising docking results for multitarget cancer compounds were observed in salicylic acid derivatives with amino acid linkages, specifically salicylic acid-curcumin, salicylic acid-benzyl alcohol, and salicylic acid-eugenol. These derivatives exhibited binding affinities towards MMP9 of -9.6, -9.6, and -8.9 kcal/mol, towards EGFR of -9.0, -7.6, and -7.9 kcal/mol, and ADP Ribose Polymerase of -11.2, -9.0, and -9.4 kcal/mol, respectively. The outcomes of the docking results highlight the significantly improved efficacy of multitarget anticancer compounds designed from salicylic acid derivatives with amino acid linkages, attributing this superiority to the enriched functional groups in the amino acid structure that enhance ligand-receptor interactions. This research contributes to identifying potential drug molecules as effective multitarget anticancer agents.

• Periodical: Engineering Headway (Volume 9)
• Pages: 23-32
• DOI: https://doi.org/10.4028/p-SVkm5P
• Online since: July 2024
• Authors: Warsito Warsito*, Masruri Masruri, Sinta Murlistyarini, Dwika Putri Pangesti, Asyfariatus Zulfa Azhar
• Keywords: Anticancer, Docking, Essential Oil, Hybridization, Linkage

References

[1] A. Pawełczyk, K. Sowa-Kasprzak, D. Olender, L. Zaprutko, "Molecular Consortia—Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis," IJMS, vol. 19, no. 4 (2018), p.1104.

DOI: 10.3390/ijms19041104

[2] E. Proschak, H. Stark, D. Merk, "Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds," J. Med. Chem., vol. 62, no. 2 (2019), pp.420-444.

DOI: 10.1021/acs.jmedchem.8b00760

[3] R. Ribeiro-Santos, M. Andrade, A. Sanches-Silva, N. R. de Melo, "Essential Oils for Food Application: Natural Substances with Established Biological Activities," Food Bioprocess Technol, vol. 11, no. 1 (2018), p.43–71.

DOI: 10.1007/s11947-017-1948-6

[4] R. Dachineni et al., "Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer," Int J Oncol, vol. 51, no. 6 (2017), p.1661–1673.

DOI: 10.3892/ijo.2017.4167

[5] H. Sidhu, N. Capalash, "Synergistic anti-cancer action of salicylic acid and cisplatin on HeLa cells elucidated by network pharmacology and in vitro analysis," Life Sciences, vol. 282 (2021), p.119802.

DOI: 10.1016/j.lfs.2021.119802

[6] L. Pinzi, G. Rastelli, "Molecular Docking: Shifting Paradigms in Drug Discovery," Int J Mol Sci, vol. 20, no. 18 (2019), p.4331.

DOI: 10.3390/ijms20184331

[7] J.E. Rundhaug, "Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res, vol. 9, no. 2 (2003), p.551–554.

[8] A.Misko, T.Ferguson, L. Notterpek, "Matrix metalloproteinase mediated degradation of basement membrane proteins in Trembler J neuropathy nerves," Journal of Neurochemistry, vol. 83, no. 4 (2002), p.885–894.

DOI: 10.1046/j.1471-4159.2002.01200.x

[9] Y. Yarden, M. X. Sliwkowski, "Untangling the ErbB signalling network," Nat Rev Mol Cell Biol, vol. 2, no. 2 (2001), p.127–137.

DOI: 10.1038/35052073

[10] J. Schlessinger, "Common and distinct elements in cellular signaling via EGF and FGF receptors," Science, vol. 306, no. 5701 (2004), p.1506–1507.

DOI: 10.1126/science.1105396

[11] J.C. Morales et al., "Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases," Crit Rev Eukaryot Gene Expr, vol. 24, no. 1 (2014), p.15–28.

DOI: 10.1615/critreveukaryotgeneexpr.2013006875

[12] A. J. Wiggans, G. K. Cass, A. Bryant, T. A. Lawrie, J. Morrison, "Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer," Cochrane Database Syst Rev, vol. 2015, no. 5 (2015), p. CD007929.

DOI: 10.1002/14651858.cd007929.pub3

[13] N. Vale, A. Ferreira, J. Matos, P. Fresco, M.J. Gouveia, "Amino Acids in the Development of Prodrugs," Molecules, vol. 23, no. 9 (2018), p.2318.

DOI: 10.3390/molecules23092318

[14] Q. Xu, H. Deng, X. Li, Z.-S. Quan, "Application of Amino Acids in the Structural Modification of Natural Products: A Review," Frontiers in Chemistry, vol. 9 (2021), Accessed: Nov. 05, 2023. [Online]. Available: https://www.frontiersin.org/articles/.

DOI: 10.3389/fchem.2021.650569